Stockpolly
Search
SGMT · NASDAQ · Biotechnology

Sagimet Biosciences (SGMT)

Develops selective FASN inhibitors for metabolic, dermatology, and oncology indications.

$11.15
Pre-market+0.15 (+1.36%)
At close$11.00(+4.76%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue200000000000
Gross profit200000000000
999111718201214111216
Research & development56561314157107712
444444555454
General & administrative444444555454
Operating income−7−9−9−11−17−18−20−12−14−11−12−16
112222221112
Interest income112222221−310
Other non-operating income−1−1−2−2−2−2−2−2−11−1−2
Income before tax−6−8−7−8−15−16−18−10−13−10−11−14
Net income from continuing operations−6−8−7−8−15−16−18−10−13−10−11−14
Net income−6−8−7−8−15−16−18−10−13−10−11−14
EPS, basic−$0.35−$0.45−$0.23−$0.25−$0.45−$0.50−$0.56−$0.32−$0.40−$0.29−$0.33−$0.26
EPS, diluted−$0.35−$0.45−$0.23−$0.25−$0.45−$0.50−$0.56−$0.32−$0.40−$0.29−$0.33−$0.26
Weighted average shares, basic181829323232323232333353
Weighted average shares, diluted181829323232323232333353
EBITDA−612−8−15−16−18−10−13−12−11−14
Depreciation & amortization099000000000
EBIT−6−8−7−8−15−16−18−10−13−12−11−14